Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16808295 | 0.94 | HRH3 (0.39) | ARICMTHRH3NR3C1PGR | |
| SCHEMBL23132941 | 0.84 | ICMT (0.36) | ICMTTRPV4 | |
| SCHEMBL19032942 | 0.84 | ICMT (0.46) | ARICMTTRPV4EGLN2 | |
| SCHEMBL7358707 | 0.80 | ICMT (0.34) | ICMTTRPV4 | |
| SCHEMBL2253176 | 0.80 | GAA (0.39) | — | |
| SCHEMBL27176780 | 0.80 | CYP19A1 (0.36) | ARICMTNR3C1PGRNR3C2 | |
| SCHEMBL30087174 | 0.80 | CYP19A1 (0.36) | ARICMTNR3C1PGRNR3C2 | |
| SCHEMBL15292538 | 0.79 | AR (0.42) | ARICMTHRH3NR3C1PGR | |
| SCHEMBL16808234 | 0.79 | MRGPRX4 (0.44) | ARICMTPTGDR2TRPV4 | |
| SCHEMBL23754946 | 0.79 | ALDH1A1 (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | AR 4327/4885ICMT 4143/4885HRH3 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.